Eflornithine Medications

Eflornithine is an enzyme inhibitor that decreases hair growth by blocking polyamine synthesis. It is applied topically to treat hirsutism in facial areas.

Vaniqa

Eflornithine

$49.30 per tube

13.9%

Select pack

About Eflornithine

Eflornithine is a synthetic analogue of the natural amino-acid ornithine that blocks the enzyme ornithine decarboxylase (ODC). By curbing polyamine synthesis, it slows the rapid cell division that drives an overabundance of facial hair and, in a completely different therapeutic arena, kills the parasite responsible for African trypanosomiasis (sleeping sickness). The molecule first entered the market in the early -s for intravenous treatment of late-stage sleeping sickness and later gained approval as a 13 % cream for the reduction of unwanted facial hair in women. Vaniqa ® is the most recognized brand, but generic formulations are widely available through our online pharmacy, offering a discreet, affordable way to access the product in Australia. While the topical indication is firmly established, clinicians occasionally explore eflornithine for other hypertrichosis conditions, though such uses remain off-label.

What is Eflornithine?

Eflornithine belongs to the class of ornithine decarboxylase inhibitors. The Therapeutic Goods Administration (TGA) approved the topical 13 % cream (Vaniqa) in 200 for the treatment of unwanted facial hair in adult women, and it continues to be listed on the Australian Register of Therapeutic Goods. The intravenous formulation received United States Food and Drug Administration (FDA) approval in 199 for second-stage Trypanosoma brucei gambiense infection and is endorsed by the World Health Organization (WHO) for this indication.

At the molecular level, eflornithine forms a covalent bond with the active site of ODC, irreversibly disabling the enzyme. In hair follicles, this reduces polyamine levels, limiting the proliferation of matrix keratinocytes that generate new hair shafts. In the parasite, ODC inhibition deprives the organism of essential polyamines, leading to arrested growth and death. Both mechanisms hinge on the same biochemical blockade but manifest in very different clinical outcomes. The product is sold under the brand Vaniqa and, in the United States, as “Eflornithine®” for trypanosomiasis; generic cream and lyophilisate versions can be purchased from our online pharmacy without the need for a brand name.

How Eflornithine Works

Mechanism of Action

Eflornithine acts as an irreversible inhibitor of ornithine decarboxylase, the rate-limiting enzyme in the polyamine synthesis pathway. By binding to the pyridoxal-5′-phosphate cofactor site, it prevents the conversion of ornithine to putrescine, the first polyamine in the cascade. The downstream shortage of spermidine and spermine hampers DNA stabilisation, RNA transcription, and cell-cycle progression.

Therapeutic Effects

In the skin, reduced polyamine production translates to slower hair-follicle turnover, producing a visible decrease in hair density after regular use. Clinical studies report up to a 30 % reduction in hair count after 8 weeks of twice-daily application. For sleeping sickness, parasite death follows loss of polyamines, leading to a cure rate exceeding 95 % when eflornithine is administered in combination with nifurtimox (the NECT regimen).

Onset and Duration

Topical eflornithine begins to show measurable hair-growth slowing within 4 weeks, with maximal benefit typically observed at 12 weeks of consistent use. The effect persists only while the cream is applied; discontinuation allows hair growth to return to baseline within a few months. Intravenous therapy for trypanosomiasis requires 14 days of dosing (four 2-hour infusions per day), after which parasite clearance is achieved and no further maintenance dosing is needed.

Approved Uses and Applications

Approved Indications

Topical 13 % cream (Vaniqa) - treatment of unwanted facial hair in adult women (TGA, Australia; FDA, USA).
Intravenous eflornithine lyophilisate - second-stage Trypanosoma brucei gambiense infection (WHO, FDA).

Off-Label Uses

Clinicians have reported using eflornithine cream for hypertrichosis due to endocrine disorders and for facial hirsutism linked to polycystic ovary syndrome. These applications lack formal regulatory approval in Australia but are supported by small-scale case series.

Clinical Efficacy

A double-blind, randomized trial published in The New England Journal of Medicine (2002) demonstrated a 31 % reduction in hair count after 8 weeks compared with placebo (p < .001). For sleeping sickness, the NECT regimen (eflornithine + nifurtimox) showed a 96 % cure rate in a multi-center study reported by The Lancet (2014), with significantly fewer relapses than historic monotherapy.

Buying Eflornithine from Our Online Pharmacy

Why Choose Our Service

Access to eflornithine can be limited by geographic distribution and pharmacy stock levels. Our online pharmacy bridges that gap, delivering the medication directly to your door while maintaining strict privacy standards.

Brand Names and Generic Options

Vaniqa ® (13 % cream, 30 g) - the most recognised brand for facial hair reduction.
Generic Eflornithine Cream - identical active ingredient, typically 20-30 % cheaper per gram.
Eflornithine Lyophilisate - sterile powder for reconstitution, used for trypanosomiasis under specialist supervision.

Quality & Safety

We work with licensed international pharmacies that operate under the oversight of the TGA and WHO-GMP standards, ensuring each batch meets rigorous purity and potency criteria.

Pricing & Access

Generic cream prices start at AU $18 per tube, while the branded Vaniqa is listed at AU $45. A Lifetime 10 % discount applies to all repeat orders placed through our platform.

Discreet Delivery

Standard shipping arrives within 3 weeks, with express options delivering in roughly 7 days. Every parcel is sealed in plain, unbranded packaging to protect your privacy.

Dosing, Formulations & Administration

Available Formulations

Topical cream - 13 % eflornithine (Vaniqa) and generic equivalents, supplied in 30 g tubes.
Intravenous lyophilisate - 100 mg vial for reconstitution (hospital use only).

Typical Dosing Ranges

For facial hair reduction, clinicians usually start patients on one pea-size amount applied twice daily to the affected areas. The dose may be adjusted upward if tolerability permits, but most adults find the standard regimen adequate. In sleeping sickness, the WHO protocol recommends 400 mg/m² infused over 2 hours, four times daily for 14 days, combined with nifurtimox.

Administration Guidelines

Topical cream should be applied to clean, dry skin and rubbed gently until fully absorbed. Use is recommended after washing the face and before applying moisturisers. Avoid contact with eyes; if accidental exposure occurs, rinse thoroughly with water. The intravenous formulation must be prepared and administered by qualified healthcare professionals in a clinical setting.

Important: The exact dose, formulation choice, and treatment duration must be determined by a qualified healthcare provider based on individual medical history and condition severity.

Safety Profile & Considerations

Common Side Effects

Local skin irritation (redness, itching) - reported in >10 % of users in phase-III trials.
Dryness or peeling - occurs in roughly 8 % of patients.
Mild burning sensation - noted in 5 % of applications.

These effects are usually transient and lessen with continued use.

Serious Adverse Events

Rare cases of severe allergic reactions (angio-edema, urticaria) have been documented; immediate medical attention is required if swelling of the face or difficulty breathing develops. Intravenous eflornithine can cause nephrotoxicity and hepatotoxicity, mandating close laboratory monitoring during therapy.

Contraindications

Known hypersensitivity to eflornithine or any cream excipients.
Pregnant or breastfeeding women - safety data are insufficient; avoid use.
Severe renal or hepatic impairment for the intravenous formulation.

Drug Interactions

Eflornithine is a substrate of renal tubular secretion and may interact with strong CYP3A4 inhibitors (e.g., ketoconazole) that alter plasma concentrations of concomitant medications. Concomitant use with other topical irritants (retinoids, benzoyl peroxide) can amplify skin reactions.

Special Populations

Older adults may experience heightened skin sensitivity; start with a reduced application frequency.
Patients with renal insufficiency require dose adjustments for the intravenous route.
Children are not a designated population for the topical product; off-label pediatric use is discouraged.

Bottom line: Always discuss your full medication list, existing health conditions, and any concerns with a healthcare professional before initiating eflornithine therapy.

Frequently Asked Questions

How does eflornithine differ from other hair-reduction treatments? Unlike laser or electrolysis, eflornithine works at the cellular level by inhibiting ODC, slowing new hair-shaft formation rather than destroying existing hair. Results accumulate gradually with continued use.
How long before eflornithine produces noticeable effects for facial hair? Most users report a visible reduction in hair density after 4-6 weeks, with optimal results achieved at 12 weeks of twice-daily application.
What should I do if I experience persistent itching from the cream? Apply a fragrance-free moisturiser after the cream has fully absorbed, and avoid using other topical actives on the same area. If irritation persists beyond a week, consult a dermatologist.
Can I use eflornithine while taking oral contraceptives? No clinically significant interaction has been identified between eflornithine cream and hormonal contraceptives; however, always inform your prescriber of all medicines you are using.
Is eflornithine safe to use during pregnancy? There are no adequate, well-controlled studies in pregnant women, and the product is classified as Category B2 in Australia. Discuss alternative options with your obstetrician.
Does taking eflornithine with food affect its absorption? The topical formulation is applied directly to the skin, so food intake does not influence its efficacy. The intravenous form is given in a clinical setting; fasting status is determined by the treating physician.
What are the main differences between the branded Vaniqa and generic cream? Both contain the same 13 % eflornithine concentration and identical inactive ingredients. Price and packaging may vary, but therapeutic outcomes are comparable.
Can eflornithine be used on other body parts besides the face? Off-label reports describe use on the chest and abdomen for hypertrichosis, but the product is formally approved only for facial application. Consult your clinician before extending use.
How should I store eflornithine cream? Keep the tube at room temperature (15-25 °C), away from direct sunlight and moisture. Do not freeze; discard any product that changes colour or develops an unusual odor.
What information should I provide my doctor when discussing eflornithine?
- Complete list of current medications, including over-the-counter drugs and supplements.
- Detailed medical history, especially skin conditions, liver or kidney disease, and pregnancy status.
- Specific goals for treatment (e.g., reduction of facial hair, management of trypanosomiasis).
- Any previous experiences with hair-removal therapies or side-effects.

Disclaimer

The information provided about eflornithine is for general knowledge only. It does not replace professional medical consultation or the official prescribing information for medications containing this ingredient. All treatment decisions, including dosing, formulation selection, and monitoring, should be made under the supervision of a qualified healthcare provider who can assess individual medical history, current medications, and specific health needs. We assume all readers are responsible adults capable of making informed decisions about their health. Our online pharmacy offers access to medications containing eflornithine for individuals who may have limited availability through traditional pharmacies, prescription-based insurance schemes, or who are seeking affordable generic alternatives. Always consult your doctor before starting, changing, or discontinuing any medication containing eflornithine.